CJC-1295 with DAC: Long-Acting GHRH Analog Mechanism, Sustained GH Elevation & Safety

What Is CJC-1295 without DAC?

CJC-1295 without DAC is a synthetic analog of human Growth Hormone-Releasing Hormone (GHRH 1-29) that stimulates natural pulsatile growth hormone (GH) release — but lacks the Drug Affinity Complex (DAC) for albumin binding. This results in a short half-life of ~30 minutes, requiring daily or twice-daily dosing.

Molecular Identity and Structure

1. Amino acid sequence: Modified 29-amino-acid chain derived from human GHRH(1-29), with four stabilizing substitutions (D-Ala2, Gln8, Ala15, Leu27) and a C-terminal amide

2. CAS Number: 863288-34-0

3. Molecular weight: 3,367.9 g/mol (C₁₅₂H₂₅₂N₄₄O₄₂)

4. Identical core to CJC-1295 with DAC, minus covalent linker

Discovery and Research Origin

Developed by ConjuChem Inc. The molecule's design rests on early GRF-analog engineering: Campbell et al. demonstrated enhanced stability and potency of tetrasubstituted GRF(1-29) analogues (Peptides, 1994). ConjuChem's own program, published as "Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor" (Endocrinology, 2005), identified CJC-1295 as a long-lasting GRF analog — that work concerns the DAC-bearing form; the no-DAC molecule is the same tetrasubstituted backbone without the albumin linker, which is why the community name Mod GRF 1-29 persists.

Legal Classification and Regulatory Status

Not approved for human use by FDA, EMA, or TGA Australia. Banned on the WADA Prohibited List under S2.2.4 — Growth Hormone Releasing Factors, which names GHRH analogues including CJC-1295 explicitly (2026 List, checked August 2026). In US compounding, FDA's December 2024 advisory-committee review proposed that all five CJC-1295 substances — including the no-DAC free base and acetate — not be included on the 503A bulks list; the July 2026 PCAC meeting did not revisit CJC-1295, so that position stands. For the full sequence of determinations, see our FDA peptide regulation timeline.

The key difference between this compound and its long-acting counterpart is the absence of the DAC albumin-binding moiety. For the extended half-life variant with weekly dosing, see our CJC-1295 with DAC long-acting GHRH science, or the side-by-side CJC-1295 vs CJC-1295 with DAC differences. Both sit within the growth hormone secretagogue class — for a complete overview, see our muscle growth and recovery peptides guide. Review CJC-1295 without DAC shop purity data from independent lab tests.

How Does CJC-1295 without DAC Work Biologically?

It binds GHRH receptors on pituitary somatotrophs → activates cAMP pathway → triggers endogenous GH pulses that mimic natural physiology.

GHRH Receptor Activation Pathway

CJC-1295 binds GHRH-R → increases intracellular cAMP → enhances GH pulse amplitude. Direct human pharmacodynamic data exists only for the long-acting DAC form: in the published trial "Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295" (JCEM, 2006), single doses raised mean plasma GH 2- to 10-fold. No published human trial quantifies the no-DAC form's GH peak — its pharmacology is inferred from the shared backbone and from GHRH physiology.

Lack of Albumin Binding

Without DAC moiety, it does not bind serum albumin → cleared rapidly via kidneys → effective duration: <1 hour

Downstream Anabolic Effects

1. Raises IGF-1 — quantified in humans only for the DAC form (1.5- to 3-fold for 9–11 days after single doses, per the JCEM trial above); no-DAC human dose-response data is unpublished

2. Collagen-synthesis and recovery effects are extrapolated from GH/IGF-1 physiology, not demonstrated in any CJC-1295-specific trial

3. Deep-sleep association reflects GH's sleep-entrained secretion; bedtime dosing is community practice, not a trial-tested protocol

4. Preserves natural GH pulsatility vs. exogenous hGH — notably, pulsatile secretion persisted even under continuous stimulation by the DAC form (JCEM, 2006)

For other short-acting GHRH analogs with similar pulsatile profiles, see our research on Mod GRF 1-29 stabilized GHRH fragment and sermorelin GHRH natural GH release.

Benefits of CJC-1295 without DAC (Based on Clinical & Community Data)

Effects derived from the DAC-form human trial, GHRH-class physiology, and widespread off-label community use — no human efficacy trial of the no-DAC form has been published.

IGF-1 Elevation and GH Release

No published human dose-response trial exists for CJC-1295 without DAC. The human IGF-1 record belongs to the DAC form: 1.5- to 3-fold elevations sustained 9–11 days after single doses in the 2006 JCEM trial. For the no-DAC form, IGF-1 elevation is expected mechanistically with repeated daily pulses but has not been quantified in a published study — a specific "+180% over 6 weeks" figure previously cited here traced to no real trial and has been removed.

Body Composition Changes

No published body-composition trial exists for CJC-1295 without DAC; lean-mass and fat-loss figures previously listed here traced to no real study. The only GHRH analog with robust human body-composition data is tesamorelin, which reduced visceral adipose tissue by roughly 15% in its Phase 3 HIV-lipodystrophy program — see our tesamorelin visceral fat GHRH science for that evidence base. Extrapolating tesamorelin's results to Mod GRF 1-29 is a hypothesis, not a demonstrated outcome.

Recovery and Anti-Aging Effects

Users report faster perceived recovery, better skin quality and improved sleep — these are anecdotal community reports; no controlled trial has measured wound healing, skin elasticity or sleep-latency endpoints for this compound.

Cardiovascular and Metabolic Markers

1. No cardiovascular-outcome or lipid data has been published for the no-DAC form

2. The DAC-form human trial reported general tolerability, not metabolic endpoints

3. Effects on glucose and insulin sensitivity beyond the short term are not established — GH elevation can reduce insulin sensitivity, which is a reason for monitoring

Side Effects and Safety Profile

Short-term tolerability appears good in community use; long-term data is absent.

Known Adverse Reactions

1. Injection-site redness or irritation (transient)

2. Post-injection flushing, warmth or mild headache (reported in GHRH-analog human studies and community reports)

3. Occasional dizziness or fatigue

4. Published incidence percentages do not exist for the no-DAC form — figures previously listed here were unsourced and have been removed

Long-Term Unknowns

1. Risk of receptor desensitization with continuous high dosing

2. Theoretical concern for tumor promotion in predisposed individuals (IGF-1 axis)

3. Impact on insulin sensitivity beyond 6 months not established

Risk Comparison Table

Dosage and Administration Protocols

No human trial has validated any no-DAC dosing protocol — the figures below document community convention, not clinical guidance.

Effective Dose Range

1. Community-standard dose: 100–200 µg/day SC

2. Split dosing: 100 µg morning + 100 µg night (for enhanced pulsatility)

3. Community protocols treat ~100 µg per injection as a "saturation dose"; no published trial verifies this ceiling

For per-injection volume and reconstitution math, use the CJC-1295 and ipamorelin calculator.

Cycle Length and Timing

Community protocol: 8–12 week cycles, followed by 4–6 week break

Peak GH spike occurs within 15–30 minutes post-injection

Best administered at bedtime to align with endogenous GH surge

Delivery Methods

1. Subcutaneous injection (standard)

2. Intranasal spray (experimental, low bioavailability)

Stacking Strategies (Community & Clinical Insights)

Popular Combinations

1. With Ipamorelin: synergistic GH release through complementary receptors (GHRH-R plus the ghrelin receptor GHS-R1a). See ipamorelin selective GH secretagogue research, the CJC-1295 and ipamorelin stack dosing protocol guide, and the CJC-1295 + Ipamorelin blend page.

2. With BPC-157: accelerated soft tissue repair and joint healing. See BPC-157 science, healing mechanism and safety.

3. With Melatonin: deeper sleep onset and amplified nocturnal GH pulse

Timing Optimization

Nighttime dosing maximizes synergy with natural GH release. Morning dose may support daytime recovery and metabolism.

For ghrelin-mimetic secretagogues that amplify GH from a different receptor, see GHRP-6 ghrelin mimetic GH stimulation and hexarelin cardioprotection and GH secretagogue research.

Where to Buy CJC-1295 without DAC Safely (Harm Reduction Guide)

Third-Party Testing Essentials

1. Demand HPLC + MS/MS certificates from shops

2. Verify batch matches CAS 863288-34-0 and the expected mass (~3,368 Da) — mass spectrometry cleanly separates the no-DAC form from the DAC form (~3,647 Da)

3. Check for correct peptide folding and absence of microbial contamination

Our guide on how to verify peptide quality before you buy provides a 6-step verification framework. Compare purity results in the Peptigrity lab tests database, browse independent testing labs, and review peptide shops ranked by trust score. For recency-weighted purity statistics per compound, see the Purity Index.

Red Flags

1. No Certificate of Analysis provided

2. Claims of "FDA-approved" or "human-grade" — illegal mislabeling

See our peptide testing guide for step-by-step instructions on sending samples to accredited labs.

Real-World User Experiences (Reddit, Podcasts, YouTube)

Anonymized Testimonials

Community reports across peptide forums most consistently describe deeper sleep within the first weeks and gradual recovery and body-composition changes over 2–3 months, typically stacked with ipamorelin. Treat all such reports as anecdotal: doses are self-selected, products are unverified, and placebo effects on sleep and recovery are strong. Two testimonials previously quoted in this section could not be traced to any real, checkable source and have been removed.

Alternatives to CJC-1295 without DAC

Pharmaceutical Options

1. Sermorelin: near-identical mechanism; formerly FDA-approved (Geref, withdrawn 2008 for commercial reasons) and now available through compounding pharmacies. See sermorelin GHRH natural GH release.

2. Recombinant hGH (Somatropin): direct replacement, higher cost, more side effects

Natural GH Stimulators

1. L-Arginine + L-Ornithine: mild effect

2. Glycine: may support sleep-related GH pulses

Comparison Chart

FAQ's

Is CJC-1295 without DAC a steroid or SARM?

No. CJC-1295 without DAC (CAS 863288-34-0) is a non-anabolic peptide that stimulates your own pituitary to release GH. For a foundational understanding, see our complete scientific guide to peptides.

Can you buy CJC-1295 without DAC legally?

Unapproved for human use by FDA, EMA, and TGA Australia. Review CJC-1295 without DAC shop purity data and CJC-1295 with DAC purity data on our platform.

Does it suppress natural GH production?

No. It enhances endogenous secretion without feedback suppression when used cyclically.

How fast do results appear?

IGF-1 responds within days of repeated dosing (shown in humans for the DAC form). Community reports describe sleep and recovery changes by week 2–4 and body-composition shifts by week 6–8 — anecdotal timelines, not trial endpoints.

Do I need PCT?

Not applicable. Does not suppress HPTA function.

What Experts Say About CJC-1295 without DAC

Trial Investigators' Perspective: Prof. Lawrence A. Frohman and colleagues

The only human CJC-1295 trial program — led with endocrinologist Lawrence Frohman as senior author — concluded that the GHRH analog produced sustained, dose-dependent GH and IGF-1 elevations while preserving pulsatile GH secretion (JCEM, 2006). That data belongs to the DAC form; the no-DAC molecule shares the backbone but was never taken through human trials.

Skeptical Perspective: Eileen Kennedy, Ph.D. (UNC Eshelman School of Pharmacy)

Speaking to NPR in March 2026 about gray-market peptides broadly, chemical biologist Eileen Kennedy cautioned: "There isn't evidence for a lot of these compounds." CJC-1295 without DAC is a textbook example — sound receptor pharmacology, essentially no compound-specific human outcome data.

Harm Reduction View

Users who proceed anyway commonly track IGF-1 bloodwork every 6–8 weeks against their age-adjusted reference range, and stop if values run persistently high. This is community-derived risk management, not medical guidance.

Community Consensus

The most consistently reported subjective benefits across community threads are improved sleep, faster recovery, and steady energy — especially stacked with ipamorelin. These are anecdotal, self-selected reports; previously cited thread counts and percentages could not be verified and have been removed.

When to Stop or Consult a Doctor

Discontinuation Triggers

1. IGF-1 persistently above the age-adjusted reference range (interpret bloodwork with a clinician)

2. Joint pain or swelling

3. Unexplained headaches or vision changes

Medical Consultation Recommended If

1. History of cancer or pre-cancerous conditions

2. Pre-existing diabetes or insulin resistance

3. Planning pregnancy or breastfeeding

Whether you are exploring short-acting or long-acting growth hormone secretagogues, the quality of your source determines your outcomes. Browse our complete peptide guide with 118 compounds (verified August 2026), compare shops through independent lab tests, and review community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.